arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Opus Genetics, Inc.

IRD
$3.70 ▼ -0.02 (-0.54%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Opus Genetics, Inc. faces fundamental challenges. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $321.5M
Dividend Yield
Revenue Growth -50.6%
Op. Margin None
ROIC 32.2%
FCF / Share $-0.15
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.03
info Valuation on last close. End-of-day price, Aug 7, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.16M
↓ -50.6%
Net Income Profit after all expenses
$-65.53M
↓ -699.8%
Operating Margin Operating profit as % of sales
-296.3%
↓ -9.8% 0th
FCF / Share Free cash flow per share
$-0.15
↑ +44.8%
Long-Term Debt Long-term obligations
$1.20M
↑ +6.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
85
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 25 years · 75 quarters